as 04-21-2025 10:38am EST
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Founded: | 1985 | Country: | United States |
Employees: | N/A | City: | MARLBOROUGH |
Market Cap: | 16.3B | IPO Year: | 1990 |
Target Price: | $84.17 | AVG Volume (30 days): | 3.7M |
Analyst Decision: | Buy | Number of Analysts: | 14 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 3.16 | EPS Growth: | 50.83 |
52 Week Low/High: | $56.27 - $84.67 | Next Earning Date: | 05-01-2025 |
Revenue: | $4,039,000,000 | Revenue Growth: | 1.76% |
Revenue Growth (this year): | 3.37% | Revenue Growth (next year): | 5.40% |
HOLX Breaking Stock News: Dive into HOLX Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Zacks
7 days ago
Simply Wall St.
7 days ago
Zacks
10 days ago
StockStory
11 days ago
MT Newswires
13 days ago
Zacks
14 days ago
Zacks
14 days ago
The information presented on this page, "HOLX Hologic Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.